137
Participants
Start Date
July 18, 2021
Primary Completion Date
December 1, 2022
Study Completion Date
December 1, 2022
Ustekinumab
No intervention or treatment will be administered as part of this study. Data available per routine clinical practice at clinic visits as well as directly from participant using a smartphone/tablet application will be collected.
Tokyo Medical and Dental University Hospital, Bunkyō City
Juntendo University Hospital, Bunkyō City
Chiba University Hospital, Chiba
Toho University Sakura Medical Center, Chiba
Kyushu University Hospital, Fukuoka
Fukuoka University Hospital, Fukuoka
Hamamatsu University Hospital, Hamamatsu
Shimane University Hospital, Izumo
Tsujinaka Hospital Kashiwanoha, Kashiwa
Saitama Medical University Saitama Medical Center, Kawagoe
University Hospital Kyoto Prefectural University of Medicine, Kyoto
Kitasato University Kitasato Institute Hospital, Minatoku
Kyorin University Hospital, Mitaka
Nagoya University Hospital, Nagoya
Okayama University Hospital, Okayama
Ishida Clinic of IBD and Gastroenterology, Ōita
Shiga University of Medical Science Hospital, Ōtsu
Sapporo Medical University Hospital, Sapporo
Tohoku University Hospital, Sendai
Tokyo Yamate Medical Center, Shinjuku-ku
Osaka Medical and Pharmaceutical University Hospital, Takatsuki
Toyama Prefectural Central Hospital, Toyama
Yokkaichi Hazu Medical Center, Yokkaichi
Lead Sponsor
Janssen Pharmaceutical K.K.
INDUSTRY